The effects of metformin on anthropometric, metabolic and hormonal changes in polycystic ovarian syndrome
- Conditions
- Polycystic ovarian syndrome.Polycystic ovarian syndrome
- Registration Number
- IRCT138903244176N1
- Lead Sponsor
- Hamedan university of medical sciences/Pro vice chancellor for research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 28
Reproductive age women referred due to infertility. Polycystic ovarian syndrome was defined as the presence of more than 12 cysts, 2–9 mm in diameter in one plane in at least one ovary and increased stroma, usually combined with increased ovarian volume >10 ml in sonography and clinical or biochemical hyperandrogenism. Subjects should have normal prolactin, thyroid, renal and hematological indices. No participant had received metformin or other hormonal treatment within the 3 months prior to study. Exclusion criteria included concurrent hormone therapy within the previous 6 weeks, any chronic disease that could interfere with the absorption, distribution, metabolism or excretion of metformin, renal or liver disease, being an smoker, doing intense physical activity, having lost 3 kg of body weight in the 2 months preceding the study
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Waist to hip cicumference. Timepoint: 12 weeks. Method of measurement: physical exam.;BMI. Timepoint: 12 weeks. Method of measurement: kilogramm/M2 physical exam.;Menstrural cycles. Timepoint: 12 weeks. Method of measurement: History taking.;Ovarian volume. Timepoint: 12 weeks. Method of measurement: Trans vaginal sonography.;Testosterone. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;LDL. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;HDL. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;TG. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;Cholestrol. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;Homocysteine. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.;CRP. Timepoint: 12 weeks. Method of measurement: Lab test, Blood sampling.
- Secondary Outcome Measures
Name Time Method Weight. Timepoint: 12weeks. Method of measurement: Physical exam.;Blood pressure. Timepoint: 12weeks. Method of measurement: Physical exam.;Acne. Timepoint: 12weeks. Method of measurement: Physical exam.;Hirsutism. Timepoint: 12weeks. Method of measurement: Physical exam.;LH. Timepoint: 12weeks. Method of measurement: Lab test, Blood sampling.;FSH. Timepoint: 12weeks. Method of measurement: Lab test, Blood sampling.;Estradiol. Timepoint: 12weeks. Method of measurement: Lab test, Blood sampling.;17OH Progesterone. Timepoint: 12weeks. Method of measurement: Lab test, Blood sampling.;DHEAS. Timepoint: 12weeks. Method of measurement: Lab test, Blood sampling.